Daré Bio CEO flags Ovaprene interim Phase 3 results as potential catalyst in investor interview

• Daré Bioscience management outlined its shift from development-stage to commercial-stage in a Virtual Investor CEO Connect interview.
• CEO Sabrina Martucci Johnson highlighted the launch of Flora Sync LF5, with DARE to PLAY Sildenafil Cream positioned as the next revenue driver.
• Plans center on building a scalable commercial infrastructure to support multiple products, with emphasis on customer acquisition, provider engagement, market access.
• Ovaprene posted positive interim Phase 3 results, with DARE-HPV advancing into Phase 2.
• Johnson flagged potential value catalysts over the next 12-18 months tied to commercialization progress, clinical milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250855PRIMZONEFULLFEED9815124) on August 25, 2026, and is solely responsible for the information contained therein.